DOCSLIB.ORG

HILIC-QTOF-HR-MS/MS for the Orthogonal (Complementary) Screening and Identification of Polar Micropollutantsin Environmental Samples

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

HILIC-QTOF-HR-MS/MS for the orthogonal (complementary) screening and identification of polar micropollutantsin environmental samples Anna Bletsou Laboratory of Analytical Chemistry Department of Chemistry University of Athens Environmental Analysis Target Suspect Non-Target Screening Screening Screening Human Technique of choice: Wide-scope Unknown metabolites – Reverse-Phase method for compounds in Environmental 2327 EPs wastewaters Liquid Chromatography TPs (RP) -MS Smart Scope of the study alternative for polar compounds HILIC wide- scope target Application of HILIC method for additional method Hydrophilic Interaction confirmation in Suspect& Non-Target LIquidChromatography Optimization- (HILIC) -MS validation- Screening application to real samples HILIC Advantages ü Retention of polar components → higher intensity ü Several different stationary phases available ü MS compatible ü Use of ACN (low viscosity solvent) → higher flow rates & better ionization ü Combination of 3 major LC techniques (NR, RP, IEX) • Complex mechanistic separation (Adsorption, Partitioning, H bonding, Ion exchange) • Great effort for the method optimization and development • More equilibration time Method development HILIC stationary phases Unmodified bare Polar chemically silica gels boned phases (c) TSKgelAmide Tosoh Bioscience (2.0 × 150 mm, 3 μm) (a) (d) Luna HILIC PHENOMENEX BEH HILIC Acquity (2.0 × 100 mm,3 (2.1 × 100 mm, 1.7 μm) μm) (b) BEH Amide Acquity (2.1 × 100 mm, 1.7 μm) (e) ZIC-pHILICSeQuant (2.1 × 150 mm, 5 μm) Method development HILIC Optimization Mobile phase •BEH Amide composition •80:20 •BEH (silica) •Luna (diol) •Ammonium Acetate •90:10 1, 5, 10 mM •ZIC-p-HILIC •95:5 •Ammonium Formate •95:5 (0.01% F.A.) •TSK-gel (amide) 1, 5, 10 mM •Formic Acid 0.01%, Stationary 0.05% Vial composition phase (ACN:H2O) M.P. (+) ESI: (A) H2O, 1mM Amm. Form. 0.01% F.A. (B) ACN:H2O (95:5), 1mM Amm. Form. 0.01% F.A. (-) ESI: (A) H2O, 10mM Amm. Form. (B) ACN:H2O (95:5), 10mM Amm. Form. § Flow rate: 200 μL/min § Column T: 40 °C § Chromatogram: 20 min (+5 min re-equilibration) Method development § Positive & Negative ESI MaXisImpact § bbCIDmode Ultra High Resolution Time-of-Flight Mass bbCIDmode Spectrometer Low CE (4 ev) (pass all) " MS spectra High CE (25 ev) (fragment all) " MS/MS spectra bbCIDmode † Target Analysis AutoMSmode † Suspect Screening † Non-target screening Database Chosen according to EPs, belonging to a 902 compounds environmental relevance diverse group of & compounds 601 well-retained compounds (k’>1) HILIC chromatographic behavior Sampling & Sample preparation Location: WWTPofAthens,Greece Period: 8th March2015(Sunday) Samples: 24-hcompositeflow-proportional influent&effluentwastewater SamplePreparation: ü 100 mL wastewater (GFF filtration) as performed in RP target screening method. ü IS spiking (100 ng/L) ü SPE Mixed-bed cartridges Strata-X ü Extraction: Neutral, Basic & Acidic Compounds Mixture: Strata-XCW, " 100 times Strata-XAW, pre-concentration ENVI+ *Kern et al. EST (2009) 43(18):7039 Method validation † validation dataset v 85 compounds v 10% of the compounds of the total database v Representative physicochemical properties v Compounds from every class of EPs † Calibration curves (solvent, matrix & spiked samples) (6 levels of concentration) † Repeatability, recoveries and matrix effect † The screening detection limit (SDL) and the limit of identification (LOI): • SDL: the lowest concentration level tested for which a compound was detected in all samples; tR + Precursor ion= 2 Identification Points (2 IPs) • LOI: the lowest concentration tested for which a compound was satisfactorily identified in all spiked samples; tR + Precursor ion + fragment = 4 Identification Points (4 IPs) Validation Results Linearity Amisulpride-N-oxide Standard addition Curve 5.E+05 Matrix-matched solutions Curve 6.E+05 4.E+05 y = 772353x + 12721 5.E+05 y = 933726x + 16903 R² = 0.9858 R² = 0.9837 ea 3.E+05 r 4.E+05 A ea r 2.E+05 A 3.E+05 2.E+05 1.E+05 1.E+05 0.E+00 0.E+00 0 0.125 0.25 0.375 0.5 0 0.125 0.25 0.375 0.5 Conc. (μg/L) Conc. (μg/L) Screening Detection Limits (SDL) –Limits of Identification (LOI) 35 30 SDL 25 es LOI t y l 20 a n 15 A % 10 5 0 0.0025 0.0125 0.025 0.05 0.25 0.5 C (μg/L) Validation Results % Recoveries 30 25 % Matrix Effect es t 20 y l a n 15 signal A % 10 suppression 5 >-50 0 <50 50-80 80-100 100-120 >120 -50 - 0 0-20 20-50 % Repeatability (n=6) 50-80 (RSD%) 80-100 § 0.25 μg/L: 3.4-16 % signal § 0.025 μg/L: 6.0-17 % enhancement § 0.0025 μg/L: 11-21 % Validation Results º Comparison RP –HILIC » 58 compounds Common in RP & HILIC validation (representative tR) Matrix Effect signal signal HILIC enhancement suppression RP >-50 -50 - 0 0-50 50-100 Validation Results º Comparison RP –HILIC » Sensitivity Slope (b), standard addition curve • 19% compounds → higher sensitivity in HILIC 11020 Due to tR ? 9 ? 100 Due to physicochemical properties ILIC 8 H 7 e 80 p 6 o l 60 /s 5 P 4 R 40 e 3 p o l 2 s 20 1 00 00 55 1010 1515 reternettieonnt tiiomn eti (mmei n)(min) Screening Detection Limit –Limit of Identification SDL-LOI • 38% compounds → lower SDL-LOI in HILIC …compounds different • 51% compounds → lower SDL-LOI in RP fragmentation pattern RP- • 11% compounds → equal SDL-LOI HILIC Validation Results º Comparison RP –HILIC » Different fragmentation pattern MS/MS spectra Spiked sample 0.5 μg/L Intens. -bbCID MS, 3.7-3.7min #423-425, Background Subtracted, Background Subtracted [%] 12.5 RP O 181.9896 O [M-H]- 10.0 S C7H5NO3S 7.5 N 181.9917 5.0 O 2.5 149.0478 165.0172 211.0508 66.0329 83.0230 95.9317 102.9567 112.9873 122.0302 134.0276 194.0876 203.9398 0.0 60 80 100 120 140 160 180 200 m/z Intens. -bbCID MS, 1.82-1.85min #391-397, Background Subtracted, Background Subtracted [%] HILIC 30 149.0611 181.9916 20 82.9539 - 190.9579 CNO3S 10 105.9604 126.9961 178.0501 105.9604 41.9991 92.9949 66.9590 78.9840 100.9260 135.0828 163.1140 199.0416 0 40 60 80 100 120 140 160 180 200 m/z Wastewater Results 336 compounds Criteria detected in total • Ion Intensity > 250 (+ESI) / 150 (-ESI) • Peak Area > 1000 (+ESI) / 600 (-ESI) • deltaRT ≤ 0.4 min Influent • Accuracy: Error ≤ 2.5 mDa wastewater 256 compounds • Isotopic fit: ≤ 100 mSigma Intens. x1056 2.0 Benzyl-dimethyl-dodecylammonium MeitsforlLeueuminccineine (Ile) 1.0 01.8.5 0.6 2-Nphe--ONn-Dyliedethsymlaemthineylvenlafaxine 1.0 cotinine 0.4 nicotine 0.5 1-7-dTimheeophthyylxliannethine Benzyl-dimethyl-dodecylammphoonOliedum-Dreinsem (teprat-hmyadld-evriopeolsxyhednollaLeeu-fmariucxneeciitneneihney l(aIlme)phetamine) 0.2 Climbazole N-DesmethyAlvmenphelafataxminieneO (xnoprrevennolaolfaxine) Caffeine cotinine v2en-ApheNmlph-a-ONfiasne-xuDyndillinepedirtem2ihdes-yephemltareamtznhiiyneynellevtehnylalafamxiinene 1-7-dTimheopethyhlyxliannethine phoOledp-VeDrroTAienparnphosamelma fmie(fstapernlueax-tdonehltdmipoopneyrrliad-dlin-dD6er -rveoD6eopeol l-xyhedno(D5pla --hmfriayNnexednephiotrneihoCrceyxoaTpleytatyhedihd-nemriraneipnemerihtneiheneytalammine)phetamine) BenBzenoBtzhenoiaBthzeioantlzerio a(CltzBeCraoil TH)ia(mrlCBezboff eobaaTe(ilfrBH)tneeubhzT roopae(oanR)BfCtleuhoT-ra3aR)brp-nCbaahaba-teay3mrd-bhrateoyzmxydepraozixynepe-i1pn0ire--a11p10cire-a-dt1cami1he-ytdamdihroy-d10ro--110--d11ih-yddihroyxydroxy N-DeNs-NmD-deDiNtsmehCm-smpyMeT4diV3dcmtrletr-evaoeThi mAenNtventp4sephelpaLthrCyaenoppho2mhara-AteBiyMleopTmdel4hid-alocttE3falmAitlrer-pyahBovAmspaiehfNiena ftrayeptsnlhyamphenc4opuriftLyeneedvthmosaphexamln2doharBmoneend1hlxea-enlitlop-yipCermuxopdoail-hopph-noy2irEtirneepmazArlneneBesbmrTDthliPolr aiNl-pneimaef-yrneoCtahdyimrctliD6yt6r iehrtcrioli-fnetamoaPmplpheened hofp1neopaneredlx2alD6hnNtadeep(yo-aediCermP hehila-r-zyxhenno2inohityepmzyNneo(exycltD6oberpemD5phtnThoPr epaanri-ilamilttoCnelteirhynt iit-rollamPrhnecrifnloaPpinm hinrvgneepolxNneayeoO(AnredixyCrenmPifyzzyoeabahenxednondci payNtpeophhVednemlycpetpeizor(homaepdiexcod anyrioiphyiMnenootepairtSoeglTnnelrtplioanrnehtmNPiradpneinCroerlivimyexaAiGA)hrterblyneafinrhAoamrneeinrCxhtfiacro CeytpezRnTedvnei VphedophlhmztiepnaphexiRaabaAn(tneerCmyedephnox(ocenbaenoneintodepheic-ryMadiepianBSneilmTahll -neanitoaolrodanNne)(acdnemloeityliia ZimrA)loVanetAGlli rtafhioneoli(ahamrfinot(neebrchpzPCRmnt ritineoelinRaPoxtiritfedpheA(oienexCrtinienienoda-rneeicadtBT)ianapephl)nemOildibaplanlhe) ihaitnerxol-riodne)acyoe(nomtenZneisrD7ol yzD)Vat aionnet irafi(n nein(P)athirtlaoCimcelPtoatilneeoe)leiinned pseTt-irnel)dOmhe) cyliopaNSfaneiir-olnoy(eneinesrolD7neMDzD)tnoo iphr-ir ninaneolacalel nx-smpirte(fcyNS fopaA)eidTriene(tneiiMa- iynerdeo(lonmr)aNDx m (fa)iidTrieA)ne)ineiy Bde(r)Nu a)fexBaumfeacxamac 0.0 1 1 2 2 3 3 4 4 5 5 6 6 7 7 Time [min] Effluent wastewater Intens. 257 compounds x105 Climbazole 1.0 Irbesartan 0.8 0.6 Amisulpride 1-54M-Meteh-yBl-enBeznoztoritarizaozleole 0.4 Benzyl-dimethyl-dovdeencylafalaxminemonium N-Desmethylventrlafmaxaidnole (norvenlafaxine) Ranitidine 0.2 Benzotriazole (BTR) Celiprolol 5-Methyl-Benzotriazole-D6 phendimetrazine Metformin Fluconazole piracetam 3 4-metho2yrt-phlrphenameeenadnadodeyitolaerixlft-needyhN-yN- rolia-nexmideeinethylamphetamine (MDMA) allaoll-oTT-HTHTFHFFHF ( A( T( llA(eTCotlletraoCeahtrtrtbaearyarthbarIdhmysahrydoamdrpyczorardoepcozrCcocteoiarcsnptrrrboiePtibasneirl-syo tDoiCmrls 8irlmoC aao5?rlrazi rbado5 rCe4-5bir?Pnp-a ma-F5aolirP-mneegbeoaPr-rzaerPmn4ezgran-dagnapyepnanegnA4ilne-ac-zAi3mneimn-ca-?et3?e10iaene-no-c-1110mt3o-a--1atim3?-di1?n-111a-11oait17-ido-idne-1p-1bidn1y-ha7-21itbry17ahin-ip-21nedyt1-yirTdp7or--eriyaT-21onet10r-er-i2o1net-1r-tl-0o1e--20tl1t11-er20-otd-r-ol-iod-hn20oneliy-he20dy)-
Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
  • The 2006 Prohibited List International Standard

    The 2006 Prohibited List International Standard

    The World Anti-Doping Code THE 2006 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2006. THE 2006 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2006 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
  • 2008 Prohibited List

    2008 Prohibited List

    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
  • Idiopathic Orthostatic Hypotension, Midodrine, and Anaesthesia

    Idiopathic Orthostatic Hypotension, Midodrine, and Anaesthesia

    499 Idiopathic orthostatic hypotension, mido- P.J. Osborne MD, L.W. Lee MD drine, and anaesthesia A patient with idiopathic orthostatic hypotension receiving Idiopathic orthostatic hypotension (IOH), which was first chronic oral midodrine therapy required amwsthesia for coro- described in 1925, ~ manifests as postural hypotension, nary arter3., bypass grafting. A perioperative infusioo of phenyl- syncope, fixed heart rate, defective sweating, nocturia ephrine was substituted ,/'or midodrine, an alpha-2 agonist, and impotence. Urinary or faecal incontinence or consti- enabling hypotension resulting from low systemic vascular pation may also occur. Inappropriate cardiovascular resistance to be controlled easily. Anticipated adrenergic reflexes2 predispose to haemodynamic instability. Treat- receptor denert,ation hypersensitivi O, was noted. The only ment is symptomatic, and includes head-up body tilt at significant perioperative problem was one episode of ~Tncope night, elastic stockings, 9 o~-fludroconisone and mido- from orthostatic hypotension during the reambulation period. drine 3 (Gutron | - Chemie Linz AG, Linz, Austria), an oral oL-adrenergic agonist in use in Europe, but an Un patient atteint d'hypolension or/hostatique idiopathique investigational drug in North America. The anaesthetic recevant un traitement oral chronique tl la midodrine a requis management of patients with autonomic dysfunction has I'anesthe;sie pour pontage aortocoronarien. Une perfusion been described, 4-9 but this is the first report of a patient pEriop~ratoire de phEnyl~phrine fut substitude ti la midodrine, with IOH receiving chronic midodrine therapy undergo- un agoniste alpha 2, a permis ~ I'hypotension r~sultant d'une ing cardiac surgery. r~sistance vasculaire syst~mique basse d'e;tre contr~l(e facile- ment.
  • View PDF Version

    View PDF Version

    Green Chemistry View Article Online PAPER View Journal | View Issue Synthesis of pharmaceutical drugs from cardanol derived from cashew nut shell liquid†‡ Cite this: Green Chem., 2019, 21, 1043 Yiping Shi, Paul C. J. Kamer § and David J. Cole-Hamilton * Cardanol from cashew nut shell liquid extracted from cashew nut shells was successfully converted into various useful pharmaceutical drugs, such as norfenefrine, rac-phenylephrine, etilefrine and fenoprofene. 3-Vinylphenol, the key intermediate for the synthesis of these drugs, was synthesised from cardanol by ethenolysis to 3-non-8-enylphenol followed by isomerising ethenolysis. The metathesis reaction worked very well using DCM, but the greener solvent, 2-methyl tetrahydrofuran, also gave very similar results. Hydroxyamination of 3-vinylphenol with an iron porphyrin catalyst afforded norfenefrine in over 70% yield. Methylation and ethylation of norfenefrine afforded rac-phenylephrine and etilefrine respectively. A sequence of C–O coupling, isomerising metathesis and selective methoxycarbonylation afforded feno- profene in good yield. A comparison of the routes described in this paper with some standard literature Creative Commons Attribution 3.0 Unported Licence. syntheses of 3-vinylphenol and of the drug molecules shows significant environmental advantages in terms of precursors, yields, number of steps, conditions and the use of catalysts. The Atom Economy of our processes is generally similar or significantly superior to those of the literature processes mainly Received 7th December 2018, because the side products produced during synthesis of 3-vinylphenol (1-octeme, 1,4-cyclohexadiene Accepted 15th January 2019 and propene) are easily separable and of commercial value, especially as they are bio-derived.
  • Plasma Catecholamines During Activation of the Sympathetic Nervous System in a Patient with Shy-Drager Syndrome

    Plasma Catecholamines During Activation of the Sympathetic Nervous System in a Patient with Shy-Drager Syndrome

    Journal of J. Neurol. 224, 125-131 (1980) Neurology © by Springer-Verlag 1980 Plasma Cateeholamines During Activation of the Sympathetic Nervous System in a Patient with Shy-Drager Syndrome G. Gross ~*, M. Nagel-Hiemke I, and K.-H. Krause 2 Pharmakologisches Institut des Universitäts-Klinikums, Hufelandstr. 55, D-4300 Essen : Neurologische Universitätsklinik, Voßstr. 2, D-6900 Heidelberg, Federal Republic of Germany Summary. Plasma catecholamines and circulation parameters were studied in a patient with a Shy-Drager syndrome. Basal values of free noradrenaline and dopamine were within the normal range, whereas the adrenaline level was de- creased. The response of plasma catecholamines to different kinds of physical activity was pathological. The inability to maintain elevated catecholamine levels during prolonged activity corresponded to impaired circulatory regu- lation and may provide an additional tool for diagnosis and monitoring of the Shy-Drager syndrome. Key words: Shy-Drager syndrome - Idiopathic orthostatic hypotension - Plasma catecholamines - Circulatory regulation. Zusammenfassung. Bei einer Patientin mit Shy-Drager-Syndrom wurden Plasmakatecholamine und Kreislaufparameter untersucht. Die basalen Werte an freiem Noradrenalin und Dopamin waren im Normbereich, Adrenalin erniedrigt. Die Reaktion der Plasmakatecholamine auf verschiedene Arten körperlicher Belastung war deutlich pathologisch. Die Unfähigkeit, die Plasmakatecholamine vor allem während längerer Aktivität auf erhöhtem Niveau zu halten, entsprach der beeinträchtigten
  • Large-Scale Phenotypic Drug Screen Identifies Neuroprotectants In

    Large-Scale Phenotypic Drug Screen Identifies Neuroprotectants In

    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.26.010009; this version posted March 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Large-scale Phenotypic Drug Screen Identifies Neuroprotectants in Zebrafish and Mouse Models of Retinitis Pigmentosa Liyun Zhang1, Conan Chen1,2, Jie Fu3, Brendan Lilley1, Cynthia Berlinicke1, Baranda Hansen1,4, Ding Ding5, Guohua Wang1,6, Tao Wang3,7,8, Daniel Shou3, Ying Ye3, Meera T. Saxena1, Kelsi R. Hall9, Abigail V. Sharrock9, Carlene Brandon10, Joong Sup Shim11, Justin Hanes3, Hongkai Ji5, Jun O. Liu12,13, Jiang Qian1, David F. Ackerley9, Baerbel Rohrer10, Donald J. Zack1, 3,14,15,16, and Jeff S. Mumm1,3,15,16 1Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA 2Current address: University of Colorado Anschutz Medical Campus 3The Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA 4Current address: St. Jude Children’s Research Hospital, Memphis, TN 5Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA 6Current address: School of Computer Science and Technology, Harbin Institute of Technology, Harbin, China 7School of Chemistry, Xuzhou College of Industrial Technology, Xuzhou, China 8College of Light Industry and Food Engineering, Nanjing Forestry University, Nanjing, China 9School of Biological
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Pharmacology of Stimulants Prohibited by the World Anti-Doping Agency (WADA)

    Pharmacology of Stimulants Prohibited by the World Anti-Doping Agency (WADA)

    British Journal of Pharmacology (2008) 154, 606–622 & 2008 Nature Publishing Group All rights reserved 0007– 1188/08 $30.00 www.brjpharmacol.org REVIEW Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) JR Docherty Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland This review examines the pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Stimulants that increase alertness/reduce fatigue or activate the cardiovascular system can include drugs like ephedrine available in many over- the-counter medicines. Others such as amphetamines, cocaine and hallucinogenic drugs, available on prescription or illegally, can modify mood. A total of 62 stimulants (61 chemical entities) are listed in the WADA List, prohibited in competition. Athletes may have stimulants in their body for one of three main reasons: inadvertent consumption in a propriety medicine; deliberate consumption for misuse as a recreational drug and deliberate consumption to enhance performance. The majority of stimulants on the list act on the monoaminergic systems: adrenergic (sympathetic, transmitter noradrenaline), dopaminergic (transmitter dopamine) and serotonergic (transmitter serotonin, 5-HT). Sympathomimetic describes agents, which mimic sympathetic responses, and dopaminomimetic and serotoninomimetic can be used to describe actions on the dopamine and serotonin systems. However, many agents act to mimic more than one of these monoamines, so that a collective term of monoaminomimetic may be useful. Monoaminomimietic actions of stimulants can include blockade of re-uptake of neurotransmitter, indirect release of neurotransmitter, direct activation of monoaminergic receptors. Many of the stimulants are amphetamines or amphetamine derivatives, including agents with abuse potential as recreational drugs.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • I (Acts Whose Publication Is Obligatory) COMMISSION

    I (Acts Whose Publication Is Obligatory) COMMISSION

    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.